Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
Date:8/8/2012

ALISO VIEJO, Calif., Aug. 8, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and nine months ended June 30, 2012.

Quarterly Financial Highlights

  • Gross and net NUEDEXTA® sales of $12.2 million and $10.1 million, respectively
  • Total company net revenues of $10.5 million
  • Cash, cash equivalents, and restricted investments of $84.1 million as of June 30, 2012
  • "Our fiscal third quarter results reflect another significant increase in net sales of NUEDEXTA seen in both our retail and institutional business," said Keith A. Katkin, president and CEO of Avanir. "Going forward, our commercial team will continue to drive revenue growth by increasing recognition of pseudobulbar affect and awareness of NUEDEXTA as the only FDA-approved treatment."

    Fiscal 2012 Third Quarter Results

  • Total net revenues for the quarter ended June 30, 2012 were $10.5 million, compared with $2.5 million for the comparable quarter in 2011. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses were $24.7 million in the third quarter of fiscal 2012, compared with $18.4 million in the comparable period in fiscal 2011.
  • Cash used in operations was $14.9 million in the third quarter of fiscal 2012.
  • Net loss for the fiscal 2012 third quarter was $15.0 million, or $0.11 per share, compared with a net loss of $16.1 million, or $0.13 per share, for the same period in fiscal 2011.
  • Nine-Month Results

  • Total net revenues for the first nine-months of fiscal 2012 totaled $27.7 million, compared with $5.7 million for the first nine-months of fiscal 2011.
  • Total operating expenses were $74.1 million in the first nine-months of fiscal 2012, compared to $48.1 million in the comparable period for fi
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
    2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    7. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    9. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    10. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
    (Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
    (Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
    (Date:10/20/2014)... Virginia (PRWEB) October 20, 2014 ... NDA Partners LLC, announced today that Ellen Teplitzky, ... legal support for the pharmaceutical industry, has joined ... manager of its legal services practice. NDA ... and expert witness and testimony, to top law ...
    Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
    ... 28, 2011 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... the WBBA Life Science Innovation Northwest Conference on Thursday, ... 607 of the Washington State Conference Center, Seattle, Washington. ... 3, 201110:25 AM PST/1:25 PM EST/7:25 PM CETRoom 607, ...
    ... a professor of chemistry at Penn State University, has developed ... zinc selenide -- a light-yellow compound that can be used ... allows for a more effective and liberal manipulation of light, ... Such technology could be applied to the development of improved ...
    ... 25, 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... and tests innovative HIV/AIDS vaccines, today announced its financial results ... GeoVax reported a net loss of $478,784 for ... a net loss of $843,275 for the comparable period in ...
    Cached Biology Technology:New kind of optical fiber developed 2New kind of optical fiber developed 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 4GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 5GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 6
    (Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
    (Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
    (Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
    Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
    ... have discovered a way to target the immune system to ... Researchers also found evidence that the same mechanism may operate ... online edition of Nature . The findings provide ... harness the immune system to fight cancer and other diseases. ...
    ... In a loud, crowded restaurant, having the ability to focus ... critical. Nerve cells in the brain face similar challenges in ... this process appears to be oxytocin, typically known as the ... bonding. , , In a study appearing online August 4 ...
    ... other international plans to evaluate obesity prevention efforts, and ... having their intended impact, says a new report from ... the report concluded that more systematic and routine evaluations ... policies are being implemented and which interventions work best. ...
    Cached Biology News:Mechanism offers promising new approach for harnessing the immune system to fight cancer 2Mechanism offers promising new approach for harnessing the immune system to fight cancer 3Study reveals potential role of 'love hormone' oxytocin in brain function 2New IOM report lays out plan to determine effectiveness of obesity prevention efforts 2
    ... MiniPrep series of robotic workstations is designed ... MiniPrep is the ideal automation platform for ... routine laboratory procedures, improving throughput, process consistency ... for MiniPrep software allows you to control ...
    Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
    ...
    ... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
    Biology Products: